July 21, 2023 07:00 AM EDTUpdated 11:45 AM
Peer Review

Ex­clu­sive: Af­ter Cure­Vac, Ig­or Splaws­ki moves to RTW stealth start­up; Lyn­dra's Jes­si­ca Ballinger adds CEO ti­tle amid com­mer­cial prep

ENDPOINTS

A chunky chain neck­lace, match­ing ear­rings, and a flo­ral shirt with a dozen col­ors — that’s Ig­or Splaws­ki.

The for­mer chief sci­en­tist at Cure­Vac has tak­en …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times